September 11, 2017 / 5:42 AM / 10 months ago

BRIEF-Janssen to discontinue Hepatitis C development program

Sept 11 (Reuters) -

* Janssen to discontinue Hepatitis C development program

* Janssen Sciences Ireland says announced decision to discontinue further development of investigational Hepatitis C treatment regimen JNJ-4178

* Janssen Sciences Ireland says decision made in light of increasing availability of number of highly effective therapies addressing medical need in Hepatitis C

* Janssen Sciences Ireland says ongoing phase ii studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter

* Janssen Sciences Ireland UC says viral hepatitis research and development to focus on addressing significant unmet needs in chronic Hepatitis B Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below